Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Carlos Jimenez-Vicente

Hospital Clinic Barcelona

1:16

Validation of adverse risk subgroups in patients with AML undergoing alloSCT

Carlos Jimenez-Vicente • 6 Jan 2025

1:15

The prognostic value of MRD in patients with AML treated with venetoclax plus HMA

Carlos Jimenez-Vicente • 6 Jan 2025

Carlos Jimenez-Vicente

Cookie settings